NCT01083316 - Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

August 31, 2013

Study Completion Date

September 4, 2020

Conditions

Amyloidosis

Interventions

DRUG

Bortezomib

"Induction:~Velcade 1.3 mg/m2/dose IV Days 1, 4, 8, 11 repeated every 21 days~Conditioning:~Bortezomib 1.0 mg/m2/dose will be administered on Days +6, -3, +1, + 4"

DRUG

Dexamethasone

"Induction:~Dexamethasone 20 mg PO/IV Days 1, 4, 8, 11 repeated every 21 days"

DRUG

Melphalan

"Conditioning:~Melphalan 70-100 mg/m2/day IV on days -2 and -1"

Trial Locations (1)

02118

Boston Medical Center, Boston